FY2028 EPS Estimate for Connect Biopharma Lifted by Analyst

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) – Stock analysts at HC Wainwright increased their FY2028 earnings estimates for Connect Biopharma in a research note issued to investors on Monday, January 26th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of ($0.79) per share for the year, up from their prior forecast of ($0.80). The consensus estimate for Connect Biopharma’s current full-year earnings is ($0.22) per share.

Several other analysts have also issued reports on CNTB. Lake Street Capital began coverage on Connect Biopharma in a report on Monday, December 1st. They set a “buy” rating and a $9.00 target price on the stock. Wall Street Zen raised Connect Biopharma to a “hold” rating in a research report on Saturday, December 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Connect Biopharma in a research note on Wednesday, January 21st. Finally, BTIG Research reissued a “buy” rating and issued a $10.00 target price on shares of Connect Biopharma in a research note on Thursday, November 13th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Connect Biopharma currently has an average rating of “Moderate Buy” and an average price target of $8.67.

Connect Biopharma Trading Down 6.4%

Connect Biopharma stock opened at $2.48 on Wednesday. The company has a market cap of $138.63 million, a price-to-earnings ratio of -3.40 and a beta of -0.19. The firm has a 50-day moving average of $2.52 and a 200-day moving average of $2.07. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.48 and a quick ratio of 5.48. Connect Biopharma has a one year low of $0.51 and a one year high of $3.28.

Connect Biopharma (NASDAQ:CNTB) last released its earnings results on Wednesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.07).

Hedge Funds Weigh In On Connect Biopharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new position in shares of Connect Biopharma in the second quarter valued at about $29,000. AlphaCore Capital LLC acquired a new position in Connect Biopharma in the 2nd quarter valued at about $78,000. Finally, Koa Wealth Management LLC bought a new position in Connect Biopharma in the 2nd quarter valued at about $49,000. 58.72% of the stock is owned by institutional investors.

About Connect Biopharma

Connect Biopharma Holdings Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for immune-mediated disorders. Headquartered in Singapore with a research and commercial presence in the United States, the company applies proprietary technology platforms to target novel pathways in inflammatory and autoimmune diseases.

The company’s lead product candidate, CBP-201, is a fully human monoclonal antibody that antagonizes the interleukin-31 receptor, a key mediator of chronic pruritus in conditions such as atopic dermatitis and prurigo nodularis.